Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1793-1801

  Toren, Paul ^a   Zoubeidi, Amina ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Akt; Combination therapy; MTOR; PI3K; Prostate cancer; Resistance

Indexed keywords

ANDROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER GROWTH; CARCINOGENESIS; ENZYME REGULATION; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84907210114     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2601     Document Type: Review

References (89)

1. 'What are the key statistics about prostate cancer?' American Cancer Society. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed April 27, 2014.
2. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187-1197, 2012.
3. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138-148, 2013.
4. Donahue TR, Tran LM, Hill R, et al: Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 18: 1352-1363, 2012.
5. Martini M, Ciraolo E, Gulluni F and Hirsch E: Targeting PI3K in cancer: Any good news? Front Oncol 3: 108, 2013.
6. Jia S, Liu Z, Zhang S, et al: Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779, 2008.
7. Jiang X, Chen S, Asara JM and Balk SP: Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 285: 14980-14989, 2010.
8. Drake JM, Graham NA, Lee JK, et al: Metastatic castrationresistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA 110: E4762-E4769, 2013.
9. Kremer CL, Klein RR, Mendelson J, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212, 2006.
10. Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20: R83-R99, 2013.
11. Dibble CC, Asara JM and Manning BD: Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29: 5657-5670, 2009.
12. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
13. Ellis L, Ku SY, Ramakrishnan S, et al: Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget 4: 2225-2236, 2013.
14. Yue S, Li J, Lee SY, et al: Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 19: 393-406, 2014.
15. Muniyan S, Ingersoll MA, Batra SK and Lin MF: Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochim Biophys Acta: Pii: S0304-419X(14)00042-0. Apr 18, 2014 (Epub ahead of print). doi: 10.1016/j.bbcan.2014.04.006.
16. Hodgson MC, Shao LJ, Frolov A, et al: Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71: 572-582, 2011.
17. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTENdeficient prostate cancer. Cancer Cell 19: 575-586, 2011.
18. Phin S, Moore MW and Cotter PD: Genomic rearrangements of in prostate cancer. Front Oncol 3: 240, 2013.
19. Fata JE, Debnath S, Jenkins EC Jr and Fournier MV: Nongenomic mechanisms of PTEN regulation. Int J Cell Biol 2012: 379685, 2012.
20. Ahmad I, Patel R, Singh LB, et al: HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci USA 108: 16392-16397, 2011.
21. Zu K, Martin NE, Fiorentino M, et al: Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 22: 1984-1993, 2013.
22. Nacerddine K, Beaudry JB, Ginjala V, et al: Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest 122: 1920-1932, 2012.
23. Dubrovska A, Kim S, Salamone RJ, et al: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273, 2009.
24. Wang S, Gao J, Lei Q, et al: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221, 2003.
25. Blando J, Portis M, Benavides F, et al: PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 174: 1869-1879, 2009.
26. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804, 2011.
27. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK and Witte ON: Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 103: 7789-7794, 2006.
28. Baca Sylvan C, Prandi D, Lawrence Michael S, et al: Punctuated evolution of prostate cancer genomes. Cell 153: 666-677, 2013.
29. Nguyen AH, Tremblay M, Haigh K, et al: Gata3 antagonizes cancer progression in Pten-deficient prostates. Hum Mol Genet 22: 2400-2410, 2013.
30. Ai J, Pascal LE, O'Malley KJ, et al: Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33: 2286-2294, 2014.
31. Thomsen MK, Ambroisine L, Wynn S, et al: SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 70: 979-987, 2010.
32. Kim MJ, Cardiff RD, Desai N, et al: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99: 2884-2889, 2002.
33. Song H, Zhang B, Watson MA, Humphrey PA, Lim H and Milbrandt J: Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28: 3307-3319, 2009.
34. Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730, 2005.
35. Blando JM, Carbajal S, Abel E, et al: Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice. Neoplasia 13: 254-265, 2011.
36. Ding Z, Wu CJ, Chu GC, et al: SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273, 2011.
37. Wang J, Kobayashi T, Floc'h N, et al: B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72: 4765-4776, 2012.
38. Thomas C, Lamoureux F, Crafter C, et al: Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 12: 2342-2355, 2013.
39. Wang Y, Kreisberg JI and Ghosh PM: Cross-Yalk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 7: 591-604, 2007.
40. Kaarbo M, Mikkelsen OL, Malerod L, et al: PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 32: 11-27, 2010.
41. Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71, 2011.
42. Wen Y, Hu MCT, Makino K, et al: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845, 2000.
43. Manin M, Baron S, Goossens K, et al: Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366: 729-736, 2002.
44. Nan B, Snabboon T, Unni E, X-J Y, Whang Y and Marcelli M: The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 31: 169-183, 2003.
45. Schwartz S, Carver B, Wongvipat J, et al: The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling. Proc 105th Annual Meeting Amer Assoc Cancer Res, abs. 4774, 2014.
46. Toren P, Kim S, Gleave M and Zoubeidi A: Combined targeting of PI3K/Akt and AR pathway with AZD5363 and enzalutamide induces anticancer activity in preclinical models of prostate cancer. J Urol 189 (Suppl l4): E403, 2013.
47. Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22, 2010.
48. Attard G, Swennenhuis JF, Olmos D, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69: 2912-2918, 2009.
49. Jendrossek V, Henkel M, Hennenlotter J, et al: Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU Int 102: 371-382, 2008.
50. Jia S, Gao X, Lee SH, et al: Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3: 44-51, 2013.
51. Sircar K, Yoshimoto M, Monzon FA, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218: 505-513, 2009.
52. Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A and Brandt B: Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 66: 8959-8965, 2006.
53. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558-565, 2011.
54. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296, 1999.
55. Dreher T, Zentgraf H, Abel U, et al: Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444: 509-517, 2004.
56. Schmitz M, Grignard G, Margue C, et al: Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 120: 1284-1292, 2007.
57. Koumakpayi IH, Le Page C, Mes-Masson AM and Saad F: Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer 102: 1163-1173, 2010.
58. Malik SN, Brattain M, Ghosh PM, et al: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171, 2002.
59. Hammarsten P, Cipriano M, Josefsson A, et al: Phospho-Akt immunoreactivity in prostate cancer: Relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 7: E47994, 2012.
60. McCall P, Gemmell LK, Mukherjee R, Bartlett JM and Edwards J: Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 98: 1094-1101, 2008.
61. Bedolla R, Prihoda TJ, Kreisberg JI, et al: Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13: 3860-3867, 2007.
62. Won JR, Gao D, Chow C, et al: A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol 26: 1438-1450, 2013.
63. Van de Sande T, Roskams T, Lerut E, et al: High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 206: 214-219, 2005.
64. Templeton AJ, Dutoit V, Cathomas R, et al: Phase 2 trial of single-Agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 64: 150-158, 2013.
65. Wagle N, Grabiner BC, Van Allen EM, et al: Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 4: 546-553, 2014.
66. Banerji U: Results of two phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors. 2013. Proc Annual Meeting Amer Assoc Cancer Res (abstract LB-66), 2013.
67. Chee KG, Longmate J, Quinn DI, et al: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5: 433-437, 2007.
68. Posadas EM, Gulley J, Arlen PM, et al: A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4: 1133-1137, 2005.
69. Bendell JC, Ervin TE, Senzer N, et al: Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 30: LBA3501, 2012.
70. Busaidy NL, Farooki A, Dowlati A, et al: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30: 2919-2928, 2012.
71. Bendell JC, Rodon J, Burris HA, et al: Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30: 282-290, 2012.
72. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F and Gross ME: Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-Yreated, castration-resistant prostate cancer. Clin Genitourin Cancer 10: 232-238, 2012.
73. Hsieh AC, Liu Y, Edlind MP, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485: 55-61, 2012.
74. Mateo J, Schoffski P, Olmos D, et al: Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man study. Mol Cancer Ther 12: B187, 2013.
75. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529, 2012.
76. Floc'h N, Kinkade CW, Kobayashi T, et al: Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 72: 4483-4493, 2012.
77. Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T and Rivera VM: Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol 41: 425-432, 2012.
78. Nakabayashi M, Werner L, Courtney KD, et al: Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 110: 1729-1735, 2012.
79. Pan C, Robles D, D'Abronzo L, et al: Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: Results from a phase I/II clinical trial. Cancer Res 72: 5750, 2012.
80. Patnaik A, Loda M, Kung J, et al: A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer. Proc 105th Annual Meeting Amer Assoc Cancer Res, abs. CT418, 2014.
81. Janne PA, Cohen RB, Laird AD, et al: Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 9: 316-323, 2014.
82. Meulenbeld HJ, de Bono JS, Tagawa ST, et al: Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol 72: 909-916, 2013.
83. Baiz D, Hassan S, Choi YA, et al: Combination of the PI3K inhibitor ZSTK474 with a PSMA-Yargeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia 15: 1172-1183, 2013.
84. Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E and Oya M: Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol 191: 227-234, 2014.
85. Lamoureux F, Thomas C, Crafter C, et al: Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res 19: 833-844, 2013.
86. Cen B, Mahajan S, Wang W and Kraft AS: Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res 73: 3402-3411, 2013.
87. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormonerefractory prostate cancer in a preclinical mouse model. J Clin Invest 118: 3051-3064, 2008.
88. Tai S, Sun Y, Liu N, et al: Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther 11: 1320-1331, 2012.
89. Festuccia C, Gravina GL, Muzi P, et al: Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 68: 965-974, 2008.